[
  {
    "question": "4 years old male patient with microcephaly, seizure, had brown hair musty odor urine,",
    "option_a": "Biotinidase deficiency",
    "option_b": "Phenylketonuria",
    "option_c": "Marble syrup",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question presents a clinical scenario typical of an inborn error of metabolism. In a young child presenting with seizures, developmental issues (microcephaly), and a characteristic body odor, the aim is to identify the metabolic disorder responsible. Phenylketonuria (PKU) results from a deficiency of the enzyme phenylalanine hydroxylase. This deficiency leads to an accumulation of phenylalanine and its neurotoxic metabolites (e.g., phenylacetate), which impart the classic \u2018musty\u2019 or \u2018mousy\u2019 odor and contribute to neurodevelopmental impairment including seizures and microcephaly if untreated. The presentation of seizures, microcephaly, and a musty odor in the urine is highly suggestive of PKU. Although classic descriptions note that untreated children with PKU often have hypopigmentation (resulting in lighter hair and skin), clinical variability exists and the musty odor remains a key diagnostic clue. Newborn screening programs routinely test for PKU by measuring blood phenylalanine levels. Confirmatory testing may include further plasma amino acid analysis and enzyme assays. Differential diagnoses include biotinidase deficiency\u2014which typically presents with alopecia, skin rash, and metabolic acidosis\u2014but lacks the characteristic musty odor. The mainstay of treatment for PKU is dietary restriction of phenylalanine with concomitant supplementation with tyrosine. Early dietary management can prevent the development of intellectual disability and seizures. In pregnant women with PKU, strict dietary management is critical because maternal PKU syndrome can cause congenital heart defects, microcephaly, and intellectual disability in the fetus. During lactation, careful monitoring of the infant\u2019s phenylalanine levels and continued dietary management are essential. Option A (Biotinidase deficiency) is associated with seizures and alopecia but does not produce a musty odor; Option B (Phenylketonuria) is classically linked to a musty odor in urine along with neurological deficits and is the correct answer; Option C (Marble syrup) is not a recognized metabolic disorder in this context. \u2022 The musty odor of urine is pathognomonic for PKU and underscores the importance of newborn screening.  \u2022 Early dietary intervention in PKU is essential to prevent irreversible neurological damage.  \u2022 Pregnant women with PKU require strict metabolic control to reduce teratogenic risks. Ongoing research in PKU includes novel therapies such as enzyme substitution therapy and studies on gene therapy. Advances in neonatal screening and dietary management continue to improve outcomes in affected patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case of a headache TGN HA, what\u2019s the best treatment. There was no Lamictal in the options",
    "option_a": "Carbamazepine",
    "option_b": "Indomethacin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Trigeminal neuralgia is a neuropathic facial pain syndrome characterized by sudden, brief, and severe lancinating pain along the distribution of the trigeminal nerve. It is a clinical diagnosis based on characteristic pain patterns and triggers. The proposed mechanism is focal demyelination of the trigeminal nerve root, frequently due to vascular compression. This demyelination leads to ectopic impulse generation and hyperexcitability. Carbamazepine acts by blocking voltage\u2010gated sodium channels, thereby reducing the abnormal firing. Patients typically present with intense, electric shock-like pain in one or more divisions of the trigeminal nerve that can be triggered by routine activities like chewing, talking, or even a breeze on the face. The rapid onset and short duration of pain episodes are hallmarks. Diagnosis is based on history and clinical examination. MRI of the brain may be used to rule out secondary causes (e.g., tumors or multiple sclerosis). Differential diagnoses include atypical facial pain, cluster headache, dental pain, and post-herpetic neuralgia. First-line treatment is carbamazepine. If patients cannot tolerate carbamazepine or have inadequate response, oxcarbazepine, lamotrigine, or even other agents may be tried. In refractory cases, surgical options such as microvascular decompression are considered. In the context of pregnancy, carbamazepine poses teratogenic risks (e.g., neural tube defects), so careful risk\u2013benefit analysis with folic acid supplementation is recommended. Option A (Carbamazepine) is the established first-line treatment for trigeminal neuralgia. Option B (Indomethacin) is used in conditions like paroxysmal hemicrania and does not address trigeminal neuralgia\u2019s pathophysiology. Options C and D were not provided. 1. Carbamazepine remains the gold standard for trigeminal neuralgia treatment. 2. Neurovascular compression leading to demyelination is the most common cause of classical trigeminal neuralgia. 3. In women of childbearing potential, the teratogenic potential of carbamazepine necessitates folic acid supplementation and close monitoring. Recent guidelines and studies continue to support carbamazepine as first-line therapy for trigeminal neuralgia, while research is ongoing into newer agents and surgical techniques for patients with refractory pain.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Hypotonic baby, colorless hair, seizures, CT brain showed? Subdural collection, what lab findings?",
    "option_a": "high cholesterol",
    "option_b": "High pyruvate/",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Menkes disease is a genetic disorder of copper metabolism, typically presenting in infancy with hypotonocity, seizures, and characteristic discolored or \u2018kinky\u2019 hair. It results from defective copper transport. Mutations in the ATP7A gene lead to impaired copper absorption and distribution, creating a systemic deficiency. This deficiency disrupts copper-dependent enzymes critical for the function of the nervous system and connective tissue, leading to neurological impairment and vascular fragility (which can manifest as subdural collections). Infants with Menkes disease are usually hypotonic, have seizures, and exhibit distinctive hair abnormalities (often described as sparse, brittle, and hypopigmented). The subdural collections result from fragile blood vessels rather than trauma, which is a key diagnostic clue. The key laboratory tests are serum copper and ceruloplasmin levels, which are typically low in Menkes disease. Differential diagnoses include non-accidental injury (child abuse), other metabolic disorders, and nutritional deficiencies; however, the unique combination of hair abnormalities and copper deficiency is characteristic. Management is largely supportive; early treatment with parenteral copper histidinate may improve outcomes, but neurological damage is often progressive. Genetic counseling is essential, especially for families with a history of the disorder. During pregnancy, prenatal diagnosis may be considered in at-risk families to guide early intervention. Option A (high cholesterol) and Option B (high pyruvate) do not correlate with Menkes disease. Option C, presumed to represent low serum copper and ceruloplasmin, is the correct laboratory finding aligning with the clinical picture. Option D was not provided. 1. The 'kinky' or discolored hair is a classic clue to Menkes disease. 2. Subdural hematomas in infants with Menkes disease are due to inherent vessel fragility, not necessarily trauma. 3. Early diagnosis and intervention with copper supplementation may modestly improve neurological outcomes. Recent research emphasizes the benefit of early copper replacement therapy in Menkes disease, although the overall prognosis remains poor. Advances in genetic screening are aiding earlier diagnosis and better family counseling.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with a seizure scenario asked about the best EEG predictor for good prognosis?",
    "option_a": "Abrupt seizure activity?",
    "option_b": "Slowing...?",
    "option_c": "Normal background",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Electroencephalography (EEG) is a key tool in evaluating epilepsy. The background rhythm of an EEG reflects the overall functional integrity of the brain and is a useful prognostic indicator. A normal background rhythm on EEG generally indicates intact cortical function and lower likelihood of underlying structural or metabolic brain abnormalities. In contrast, diffuse slowing or interictal epileptiform discharges might reflect brain dysfunction and are associated with a poorer prognosis. Patients with a normal interictal EEG background are more likely to have benign epilepsy syndromes and a favorable response to antiepileptic drug therapy, whereas significant abnormalities suggest a more severe or secondary epilepsy disorder. When evaluating a patient with seizures, the EEG helps distinguish between various epilepsy syndromes. Differential diagnoses based on EEG findings include focal slowing (which may indicate a structural lesion) and generalized epileptiform discharges (indicative of generalized epilepsy). A normal background in the context of seizures is reassuring regarding overall brain function. While EEG findings do not directly dictate the choice of therapy, a normal background is associated with better prognosis and may influence long-term management strategies. In pregnant patients, maintaining seizure control while minimizing drug side effects is crucial, and EEG can be useful for monitoring response to therapy. Option A (abrupt seizure activity) does not reliably predict a good prognosis. Option B (slowing) typically indicates underlying cerebral dysfunction. Option C (normal background) is the most favorable finding on EEG and is thus the correct answer. Option D was not provided. 1. A normal EEG background is a reassuring prognostic sign in epilepsy. 2. Diffuse slowing on EEG often points to an underlying structural or metabolic issue. 3. EEG remains a cornerstone in both diagnosis and prognostication in epilepsy management. Current research reinforces that a normal interictal EEG background is correlated with a favorable clinical course in epilepsy. Ongoing studies are aimed at identifying additional EEG biomarkers that can further refine prognostic assessments.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Female epileptic patient on 2 AED still not controlled want to try a new released one?",
    "option_a": "Needs Saudi FDA approve",
    "option_b": "not to interfere with pregnancy",
    "option_c": "Not to have drug-drug interaction",
    "option_d": "not to elevate her liver enzymes",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "In female patients with epilepsy, especially those of childbearing age, the selection of antiepileptic drugs (AEDs) must balance seizure control with the potential impact on pregnancy. New AEDs should be evaluated not only for efficacy but also for their safety profile in reproductive health. AEDs can interfere with hormone levels and metabolism, potentially affecting contraceptive effectiveness and fetal development. Enzyme-inducing AEDs may lower levels of concomitant medications, alter folate metabolism, and increase the risk of teratogenic outcomes. Women with refractory epilepsy, who may require the addition of a new AED, must consider the risk of teratogenicity and adverse pregnancy outcomes. The proper choice of medication can minimize interference with reproductive hormones and reduce potential fetal risks. While the decision to change or add a medication is clinical, it requires a thorough review of the patient\u2019s reproductive plans, current drug regimen, and potential drug\u2013drug interactions. Counseling and monitoring, including serum drug levels and folate levels, are integral parts of the management plan. First-line management in women of childbearing potential favors AEDs with low teratogenic risk (e.g., lamotrigine and levetiracetam). For a new AED to be considered in a patient who is already on polytherapy, it should ideally have a minimal interaction profile, not interfere with hormonal balance, and have a low risk of teratogenicity. In pregnancy and lactation, rigorous counseling, therapeutic drug monitoring, and, if needed, dose adjustments are essential. Option A (Saudi FDA approval) refers to regulatory clearance and is not a primary clinical consideration. Option B (not to interfere with pregnancy) addresses the highest priority in women of childbearing potential by minimizing teratogenic risk and hormonal interactions, making it the best answer. Option C (not to have drug\u2013drug interactions) is important but secondary to ensuring reproductive safety. Option D (not to elevate liver enzymes) is less critical in this context. 1. In women of reproductive age, AED selection should always consider potential teratogenic effects and interactions with hormonal contraception. 2. Enzyme-inducing AEDs can reduce the efficacy of contraceptive methods, leading to unplanned pregnancies. 3. Counseling about pregnancy and lactation is essential when initiating or modifying AED therapy. Latest guidelines emphasize the use of AEDs with favorable reproductive safety profiles in women of childbearing potential. Current research focuses on pharmacovigilance regarding teratogenic outcomes and drug\u2013drug interactions to better tailor epilepsy management in this population.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came with history of right early non forced head turning & right-side automatism, localization?",
    "option_a": "rt frontal",
    "option_b": "rt temporal",
    "option_c": "lt frontal",
    "option_d": "lt temporal",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Ictal semiology provides important localization clues. In temporal lobe seizures, especially those arising from the mesial or lateral temporal regions, patients often exhibit subtle features such as ipsilateral automatisms and non\u2010forced head turning. Temporal lobe seizures typically involve abnormal electrical discharges in the limbic structures (hippocampus, amygdala, parahippocampal gyrus) leading to behavioral automatisms. The non\u2010forced, early head turning toward the side of the discharging temporal lobe is thought to result from ipsilateral spread without strong involvement of the frontal eye field, which would otherwise produce a forced and contralateral deviation. Patients with temporal lobe epilepsy may present with complex partial seizures marked by subtle but stereotyped automatisms (e.g., lip smacking, fumbling) and a mild head version that is ipsilateral to the seizure focus. The absence of a forced head turn helps differentiate these seizures from frontal lobe seizures. Important differentials include frontal lobe seizures (often characterized by forced, contralateral head version and brief duration), psychogenic nonepileptic events, and other causes of altered awareness. Video-EEG monitoring with simultaneous clinical observation remains the cornerstone of seizure localization and classification. First-line management includes starting appropriate antiepileptic drugs (AEDs) such as levetiracetam, lamotrigine, or carbamazepine for focal seizures. The choice of AED is tailored to the seizure type, patient comorbidities, and if applicable, pregnancy and lactation considerations (e.g., avoiding valproate in pregnant women, ensuring folic acid supplementation with enzyme\u2010inducing drugs). In refractory cases, further evaluation for epilepsy surgery may be considered. Option A (rt frontal) is more consistent with forced head deviation seen in frontal lobe seizures. Options C (lt frontal) and D (lt temporal) point to the opposite hemisphere. Option B (rt temporal) correctly corresponds to the side (right) and the temporal lobe characteristics indicated by automatisms and non-forced head turning. 1. In temporal lobe seizures, ipsilateral automatisms and subtle, non\u2010forced head turning are common. 2. Forced head version is more indicative of frontal lobe involvement. 3. Detailed semiologic analysis is critical for proper epilepsy localization. Recent studies using video-EEG and advanced imaging techniques continue to validate the utility of ictal semiology in localizing seizure onset zones. Current guidelines recommend a detailed clinical history and corroborative electrophysiologic data to differentiate temporal from frontal lobe seizures.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario about Rasmussen syndrome (hints: partial seizure progress to be GTC\u2026) with perisylvian atrophy on the side of the symptoms. What is the related antibody?",
    "option_a": "Anti GLUR3",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Rasmussen encephalitis (or Rasmussen syndrome) is a rare chronic inflammatory neurological disorder usually seen in children that typically presents with intractable focal seizures and progressive neurological deterioration. While the exact mechanism is not completely understood, an autoimmune process has been implicated in its pathogenesis. Autoantibodies, especially Anti-GluR3 (a glutamate receptor subtype), have been identified in some patients, suggesting a potential role in mediating neuronal injury and the associated epileptogenesis. Clinically, Rasmussen encephalitis manifests as focal seizures that may progress to generalized tonic\u2010clonic seizures and is frequently accompanied by progressive unilateral hemispheric atrophy (often involving perisylvian regions). The presence of such imaging findings along with the clinical picture are strongly suggestive of the diagnosis. Differential diagnoses include cortical dysplasia, brain tumors, and other immune-mediated encephalitides. Diagnosis is supported by neuroimaging (MRI showing unihemispheric atrophy), EEG findings, and, in select cases, cerebrospinal fluid (CSF) analysis. While the role of anti-GluR3 is controversial, its presence can support the diagnosis. Initial treatment strategies include immunotherapy (steroids, IVIG, plasmapheresis) to modulate the immune response. When medical therapy fails and seizures remain intractable, surgical interventions such as functional hemispherectomy might be indicated. In pregnant or lactating patients, management must balance maternal benefits with fetal safety, often employing immunomodulatory therapies with careful monitoring and steroid-sparing protocols where possible. Option A (Anti-GluR3) is the traditionally cited antibody related to Rasmussen syndrome. Although the pathogenic role of anti-GluR3 antibodies remains under investigation and is not found in all patients, among the choices provided it is the one most classically linked with the condition. 1. Rasmussen encephalitis is typically unihemispheric, leading to progressive atrophy on the affected side. 2. Anti-GluR3 antibodies, despite controversies, are historically associated with the disease. 3. Early immunotherapy may alter disease progression. Recent research continues to explore the immunologic underpinnings of Rasmussen encephalitis, and while anti-GluR3 antibodies are not universally present, they remain an important historical and research marker. Current guidelines emphasize early recognition and immunotherapy, with surgical intervention reserved for refractory cases.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "What\u2019s the 2-year recurrence of seizure after the first attack?",
    "option_a": "30%",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "After a first unprovoked seizure, clinicians must evaluate the risk of recurrence for subsequent seizures. This recurrence risk is a crucial factor when deciding on the initiation of long-term antiepileptic drug (AED) therapy. The recurrence after a first seizure is thought to be related to underlying neuronal hyperexcitability, which may be due to structural, genetic, or metabolic factors. A first seizure may unmask an intrinsic predisposition toward epileptic discharges. In clinical practice, the risk of recurrence has been estimated using various prognostic models, and the two-year recurrence rate after a first unprovoked seizure generally falls around 30% to 40%. The exact risk may depend on additional factors such as EEG abnormalities or neuroimaging findings. The clinician should differentiate between provoked and unprovoked seizures, assessing risk factors such as abnormal neuroimaging, EEG findings, and patient history. Differential diagnoses include syncope, psychogenic seizures, metabolic disturbances, and transient ischemic events. Assessment tools and scoring systems may help refine recurrence risk estimation. According to current guidelines, AED therapy is typically considered when the estimated risk of seizure recurrence is sufficiently high (often cited as >60% over 10 years in some definitions) or in the presence of other high-risk features (e.g., abnormal EEG or neuroimaging). Initial management may be conservative with close follow-up; however, many studies report that the 2-year recurrence risk is about 30%, which is an important statistic for counseling patients. Option A (30%) is within the accepted range for a 2-year recurrence risk following a first unprovoked seizure. Other options, if provided, would likely overestimate or underestimate the risk. The 30% estimate helps reassure that while there is a significant risk of recurrence, not all patients will necessarily experience another seizure. 1. Roughly one-third of patients will recur within two years after a first unprovoked seizure. 2. Risk assessment should include EEG and neuroimaging. 3. Decision-making for AED initiation is individualized based on recurrence risk and patient factors. Recent meta-analyses and guidelines continue to support a recurrence risk in the ballpark of 30%-40% after a first unprovoked seizure. These findings help inform discussions with patients regarding the risks and benefits of AED therapy.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came with multiple times decrease LOC to ER, what\u2019s the most important thing when you see you need to start AED?",
    "option_a": "Up rolling of eye",
    "option_b": "lack of awareness",
    "option_c": "post ictal confusion",
    "option_d": "GTC seizure",
    "option_e": "???",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "When evaluating a patient with recurrent episodes of decreased level of consciousness (LOC), distinguishing epileptic seizures from other causes (such as syncope or psychogenic events) is essential. One of the hallmark features that indicates an epileptic event is the presence of a postictal state. During an epileptic seizure, abnormal synchronous neuronal discharges lead to transient cerebral dysfunction. Following the ictal event, there is often a period of neuronal recovery marked by postictal confusion, which results from metabolic exhaustion and transient disruption in neural network activity. Postictal confusion is commonly observed after true epileptic seizures and is characterized by impaired awareness, disorientation, and sometimes fatigue. It helps to differentiate epileptic events from other causes of transient LOC, such as syncope where recovery is typically rapid and complete without a prolonged confusion period. The differential diagnosis for episodes of decreased LOC includes epileptic seizures, syncope, transient ischemic attacks, and psychogenic nonepileptic seizures. A careful clinical history focusing on the presence or absence of a postictal state, duration of loss of consciousness, and associated motor phenomena is critical. Video-EEG monitoring may be required for definitive classification. The decision to initiate AED therapy depends on the accurate diagnosis of epilepsy. For patients with clear evidence of epileptic seizures\u2014especially those with generalized tonic-clonic events or focal seizures with impaired awareness confirmed by postictal confusion\u2014first-line AEDs are recommended. When treating women who are pregnant or lactating, it is imperative to choose AEDs with lower teratogenicity (avoiding valproate when possible) and to supplement with folic acid as recommended. Option A (up rolling of eyes) is a non-specific finding seen in both epileptic and non-epileptic events; Option B (lack of awareness) can be present in both focal impaired awareness seizures and non-epileptic disorders; Option D (GTC seizure) is indeed an important seizure type that mandates AED initiation but in the context of recurrent episodes with decreased LOC, it is the confirmation of a postictal state that helps distinguish true epileptic seizures from other mimics. Therefore, Option C (postictal confusion) is the most reliable clinical sign in this scenario. 1. Postictal confusion is a key indicator that a patient has experienced an epileptic seizure rather than syncope or a psychogenic event. 2. Accurate identification of the postictal state is crucial for the diagnosis and management of epilepsy. 3. Detailed seizure semiology aids in the selection and timing of AED initiation. Recent guidelines on epilepsy emphasize that the presence of a postictal state is a strong clinical clue favoring an epileptic event. This helps in differentiating seizures from other causes of transient LOC and guides timely initiation of AED therapy when indicated.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Female patient k/c epilepsy, has seizures more frequently on menstruation asked about Pathophysiology?",
    "option_a": "Estradiol lower seizure threshold",
    "option_b": "Progesterone lower seizure threshold",
    "option_c": "Seizure cluster around ovulation",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Catamenial epilepsy refers to the pattern of increased seizure frequency in relation to the menstrual cycle. It is based on the premise that fluctuations in sex hormones\u2014especially estrogen and progesterone\u2014affect neuronal excitability. Estrogen, particularly estradiol, has a proconvulsant effect, while progesterone (and its neuroactive metabolites like allopregnanolone) exerts anticonvulsant effects. During the perimenstrual phase, there is a relative predominance of estradiol as progesterone levels drop. Estradiol enhances excitatory synaptic transmission (for example, by potentiating glutamatergic activity) and can lower the seizure threshold. On the other hand, progesterone usually increases inhibitory tone via GABAergic modulation. The imbalance, with estradiol\u2019s effect prevailing during menses, underlies the increased seizure frequency seen in catamenial epilepsy. Patients with catamenial epilepsy report worsening seizure frequency around menstruation. The clinical pattern is linked to predictable hormonal fluctuations that modulate neuronal excitability, making these patients particularly vulnerable during specific phases of their menstrual cycle. Diagnosis is primarily clinical, based on a clear temporal relationship between the menstrual cycle and seizure occurrence. Differential diagnoses include other exacerbations of focal seizures not related to hormonal changes. In some cases, hormonal assays or a seizure diary may help correlate cycle phases with seizure events. Management involves optimizing antiepileptic drug (AED) regimens and may include cyclic therapy adjustments. First-line interventions can involve modifying the dosage regimen of the current AED around the menstrual cycle. In some cases, supplemental cyclic progesterone therapy or hormonal modulation (e.g., using gonadotropin\u2010releasing hormone analogs) is considered. When managing women during pregnancy and lactation, careful consideration must be given to AED teratogenicity and hormonal manipulations; folate supplementation is recommended and the risks and benefits of hormonal treatments must be discussed. Option A (Estradiol lowers seizure threshold) is correct because estradiol\u2019s proconvulsant properties contribute to the pathophysiology of catamenial epilepsy. Option B is incorrect as progesterone actually has anticonvulsant effects. Option C (Seizure cluster around ovulation) does not explain seizures that occur specifically around menstruation. 1. Remember that estrogen tends to be proconvulsant while progesterone is protective. 2. In catamenial epilepsy, seizure patterns often correlate with the cyclic variations in these hormones. 3. Therapeutic strategies sometimes include adjusting AED dosing during vulnerable periods. Recent studies and clinical guidelines continue to support the role of sex hormone fluctuations in seizure modulation. Research into hormonal therapies\u2014including the use of cyclic progesterone supplementation and other endocrine interventions\u2014has provided additional strategies for patients with catamenial epilepsy.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case of MTLE? (Attached picture of MRI brain) Patient on maximum dose keppra next?",
    "option_a": "Tegretol",
    "option_b": "phenytoin",
    "option_c": "Lamictal",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Mesial Temporal Lobe Epilepsy (MTLE) is one of the most common focal epilepsies and is frequently associated with hippocampal sclerosis. It is typically characterized by complex partial seizures with impaired awareness. MTLE often results from sclerosis (scarring) of the mesial temporal structures such as the hippocampus. This structural alteration leads to abnormal excitatory circuitry, promoting recurrent seizure activity. Because of changes in neuronal networks, seizures in MTLE may be resistant to standard monotherapy. Patients with MTLE usually present with features such as aura, impaired awareness during seizures, and sometimes secondary generalization. MRI often reveals hippocampal atrophy or sclerosis, and EEG studies tend to show temporal lobe epileptiform discharges. Diagnosis is based on a detailed clinical history, EEG findings, and neuroimaging, particularly MRI. Differential diagnoses include other types of focal epilepsy (such as frontal or occipital lobe epilepsy) and non-epileptic events. MRI findings help differentiate MTLE (with mesial temporal sclerosis) from other pathologies. First-line treatment of focal seizures in MTLE generally includes AEDs such as carbamazepine, lamotrigine, and levetiracetam. Since the patient is already on a maximum dose of levetiracetam (Keppra), adding lamotrigine (which is effective for focal seizures and has a favorable side-effect profile) represents a rational next step. In patients of childbearing potential, lamotrigine is preferred due to its comparatively lower teratogenic risk; however, serum levels may change in pregnancy, necessitating close monitoring. During lactation, lamotrigine is excreted in breast milk but is generally considered acceptable with monitoring. Option A (Tegretol/carbamazepine) is a classic alternative and is a viable option; however, lamotrigine (Option C) is also supported by guidelines because of its efficacy and tolerability as adjunctive therapy. Option B (Phenytoin) is less favored due to its narrow therapeutic index and side-effect profile. The marked answer, lamotrigine, is therefore acceptable as a next-line agent after failure of levetiracetam monotherapy. 1. When initial monotherapy fails in MTLE, consider a rational combination of AEDs with complementary mechanisms. 2. Lamotrigine is well recognized for its effectiveness in focal epilepsies with a good side-effect profile. 3. Surgical evaluation is an option for drug-resistant MTLE if pharmacologic management fails. Recent guidelines by the International League Against Epilepsy (ILAE) and other epilepsy organizations endorse lamotrigine as an effective option in focal epilepsies, including mesial temporal lobe epilepsy, either as monotherapy or as adjunctive therapy, especially when patients are not adequately controlled on a single agent.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly with a history of inability to care for himself, decreased LOC, what to find on EEG?",
    "option_a": "Diffuse Slowing",
    "option_b": "PLED",
    "option_c": "Sharp and waves",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "EEG is an essential tool for assessing brain activity, particularly in conditions of global cerebral dysfunction. Diffuse slowing on EEG generally indicates a generalized encephalopathy rather than a focal seizure disorder. Diffuse slowing represents widespread cortical dysfunction. In elderly patients who are acutely or chronically encephalopathic\u2014due to metabolic disturbances, toxic exposures, or other causes\u2014the normal fast activity (alpha and beta rhythms) is replaced with slower frequency waveforms (theta or delta ranges). An elderly patient presenting with decreased level of consciousness (LOC) and an inability to care for himself is likely suffering from a diffuse metabolic or toxic encephalopathy. This clinical picture is reflected on EEG by generalized slowing rather than focal epileptiform discharges. While EEG does not specify the underlying cause of encephalopathy, it is a sensitive indicator of global cerebral dysfunction. Differential diagnoses include metabolic encephalopathies, toxic drug effects, and postictal states. Focal EEG abnormalities such as periodic lateralized epileptiform discharges (PLEDs) or localized sharp waves suggest focal brain lesions and are not typical in diffuse encephalopathy. Management is primarily aimed at identifying and treating the underlying cause of encephalopathy. In elderly patients, this may involve correction of metabolic derangements, managing infections, or discontinuing sedative medications. In the context of pregnancy and lactation, EEG findings remain similar; however, the evaluation of any underlying metabolic cause must be undertaken with attention to fetal and neonatal safety. Option A (Diffuse Slowing) is correct as it is the classic EEG finding in a patient with a generalized encephalopathy. Option B (PLED) is typically associated with focal lesions such as stroke or acute seizure activity and is not consistent with a diffuse process. Option C (Sharp and waves) denotes epileptiform discharges seen in focal or generalized seizure disorders, which does not match the clinical scenario of a diffuse encephalopathic state. 1. Diffuse slowing on EEG is a common and sensitive indicator of generalized brain dysfunction. 2. In elderly patients, metabolic or toxic encephalopathies are frequent causes of altered mental status. 3. Always consider and correct the underlying systemic condition when faced with such EEG findings. Current research and clinical practice guidelines continue to support the use of EEG as an adjunct in diagnosing various forms of encephalopathy. Diffuse slowing remains a consistent marker of global cerebral dysfunction in both acute and chronic settings.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Young female was brought by her family due to bizarre nocturnal hyperactive abnormal movement, similar history in her family, what is the AED to start. ADN FLE.",
    "option_a": "Zonisamide can be used.",
    "option_b": "",
    "option_c": ") is presumed to represent carbamazepine, which is supported by the bulk of evidence and clinical guidelines as the treatment of choice for ADNFLE. The fact that the option text for C is missing in the prompt suggests a possible oversight; however, based on standard management, carbamazepine is the preferred agent.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE) is a distinct epilepsy syndrome characterized by seizures that occur primarily during sleep. It is often triggered by genetic mutations affecting ion channels or receptor function, particularly involving nicotinic acetylcholine receptors. ADNFLE is commonly associated with mutations that alter the function of neuronal ion channels or receptors, leading to hyperexcitability in the frontal lobes. These seizures manifest as brief, often stereotyped motor events during sleep. The familial (autosomal dominant) pattern underscores the genetic basis of the disorder. Patients with ADNFLE typically present with bizarre, hyperkinetic, nocturnal events that may be mistaken for parasomnias. A positive family history is common and serves as an important diagnostic clue. Episodes are usually brief and may involve complex motor behaviors, sometimes with preserved awareness. Diagnosis is based on a combination of clinical history, video EEG monitoring during sleep, and family history. Differential diagnoses include sleep disorders such as parasomnias (e.g., sleepwalking, REM sleep behavior disorder) and other forms of frontal lobe epilepsy. Detailed history and prolonged video EEG recordings are key to differentiating ADNFLE from non-epileptic events. The first-line treatment for ADNFLE is typically a sodium channel blocker such as carbamazepine. Carbamazepine (or oxcarbazepine as an alternative) is effective in reducing the frequency and severity of seizures in ADNFLE. Although zonisamide (Option A) may be used as an alternative in some cases, it is not the traditional first-line agent. In women of childbearing potential, caution is warranted with carbamazepine due to its teratogenic risk (notably neural tube defects), so folate supplementation is important; during lactation, while carbamazepine is excreted in breast milk, it is generally considered acceptable with proper monitoring. Option A mentions zonisamide, which can be used in focal epilepsies, but it is not the conventional first-line therapy for ADNFLE. The marked answer (Option C) is presumed to represent carbamazepine, which is supported by the bulk of evidence and clinical guidelines as the treatment of choice for ADNFLE. The fact that the option text for C is missing in the prompt suggests a possible oversight; however, based on standard management, carbamazepine is the preferred agent. 1. ADNFLE often masquerades as a non-epileptic sleep disorder; a careful history and family pedigree are essential for diagnosis. 2. Carbamazepine is the mainstay treatment for ADNFLE, with proven efficacy in controlling nocturnal frontal lobe seizures. 3. Always consider the teratogenic potential of AEDs in women of childbearing age and ensure appropriate folate supplementation. Recent studies and clinical practice guidelines continue to favor carbamazepine as first-line therapy for ADNFLE due to its mechanism of stabilizing hyperexcitable neuronal membranes. While newer alternatives are being explored, the evidence supporting carbamazepine in genetically mediated frontal lobe epilepsies remains robust.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Not sure about the Q but MRI with MTLE? Asked about what type of aura a patient will have?",
    "option_a": "Cephalic",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Mesial Temporal Lobe Epilepsy (MTLE) is characterized by focal seizures that typically begin in the medial structures of the temporal lobe. Auras, which are the patient\u2019s initial manifestations of seizure activity, are important in localizing the epileptogenic zone. In MTLE, the classic aura is an epigastric rising sensation rather than a cephalic (head\u2010centered) sensation. In MTLE, abnormal electrical discharges often originate from the hippocampus, amygdala, or parahippocampal structures. This ictal activity produces autonomic symptoms by influencing limbic and visceral network pathways, resulting in manifestations such as the epigastric aura. Functional neuroimaging and electrophysiological studies have confirmed this association. Patients with MTLE frequently experience a prodrome of sensations described as an epigastric rising sensation (\u2018butterflies in the stomach\u2019), sometimes accompanied by fear or d\u00e9j\u00e0 vu. This differs from a cephalic aura, which is less typical in mesial temporal lobe onset seizures. Diagnosis relies on detailing the clinical history of auras, supported by video EEG monitoring and high\u2010resolution MRI (which may reveal hippocampal sclerosis). Differential diagnoses include other focal epilepsies (e.g., frontal lobe epilepsy), where auras tend to be motor or sensory rather than autonomic. First-line management of MTLE involves anti-epileptic drugs (AEDs) such as carbamazepine, levetiracetam, or lamotrigine. In medically refractory cases, epilepsy surgery may be considered. In women who are pregnant or planning pregnancy, AED selection is critical; alternatives with lower teratogenic risks (e.g., lamotrigine or levetiracetam) may be preferred along with folate supplementation if carbamazepine is used. Option A (Cephalic aura) does not align with the typical presentation of MTLE. Option B, which presumably stands for an epigastric aura, is the classical feature seen in MTLE. Therefore, the marked answer B is correct. 1. An epigastric rising sensation is the hallmark aura in mesial temporal lobe epilepsy. 2. Hippocampal sclerosis on MRI is strongly suggestive of MTLE. 3. A precise semiological description of the aura aids localization and treatment planning. Recent guidelines and studies emphasize the importance of detailed seizure semiology in localizing epileptogenic zones. Advances in MRI techniques have enhanced the detection of subtle mesial temporal abnormalities, and a variety of AEDs are now available to tailor treatment based on efficacy, side-effect profile, and patient-specific factors.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with frontal lobe epilepsy on AED, since the age of 15 years she did not have any seizures and now she is 18 years of age and she wants to stop the medication. Risk of seizure recurrence?",
    "option_a": "Abrupt withdrawal of carbamazepine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Mesial Temporal Lobe Epilepsy (MTLE) is characterized by focal seizures that typically begin in the medial structures of the temporal lobe. Auras, which are the patient\u2019s initial manifestations of seizure activity, are important in localizing the epileptogenic zone. In MTLE, the classic aura is an epigastric rising sensation rather than a cephalic (head\u2010centered) sensation. In MTLE, abnormal electrical discharges often originate from the hippocampus, amygdala, or parahippocampal structures. This ictal activity produces autonomic symptoms by influencing limbic and visceral network pathways, resulting in manifestations such as the epigastric aura. Functional neuroimaging and electrophysiological studies have confirmed this association. Patients with MTLE frequently experience a prodrome of sensations described as an epigastric rising sensation (\u2018butterflies in the stomach\u2019), sometimes accompanied by fear or d\u00e9j\u00e0 vu. This differs from a cephalic aura, which is less typical in mesial temporal lobe onset seizures. Diagnosis relies on detailing the clinical history of auras, supported by video EEG monitoring and high\u2010resolution MRI (which may reveal hippocampal sclerosis). Differential diagnoses include other focal epilepsies (e.g., frontal lobe epilepsy), where auras tend to be motor or sensory rather than autonomic. First-line management of MTLE involves anti-epileptic drugs (AEDs) such as carbamazepine, levetiracetam, or lamotrigine. In medically refractory cases, epilepsy surgery may be considered. In women who are pregnant or planning pregnancy, AED selection is critical; alternatives with lower teratogenic risks (e.g., lamotrigine or levetiracetam) may be preferred along with folate supplementation if carbamazepine is used. Option A (Cephalic aura) does not align with the typical presentation of MTLE. Option B, which presumably stands for an epigastric aura, is the classical feature seen in MTLE. Therefore, the marked answer B is correct. 1. An epigastric rising sensation is the hallmark aura in mesial temporal lobe epilepsy. 2. Hippocampal sclerosis on MRI is strongly suggestive of MTLE. 3. A precise semiological description of the aura aids localization and treatment planning. Recent guidelines and studies emphasize the importance of detailed seizure semiology in localizing epileptogenic zones. Advances in MRI techniques have enhanced the detection of subtle mesial temporal abnormalities, and a variety of AEDs are now available to tailor treatment based on efficacy, side-effect profile, and patient-specific factors.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with seizure associated hypersalivation\u2026, localization?",
    "option_a": "Insula",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "In focal seizures, autonomic signs such as hypersalivation suggest involvement of brain regions that regulate visceral functions. The insular cortex, due to its extensive connections with autonomic and gustatory networks, is classically linked to such ictal manifestations, making it a key target for localization in patients with hypersalivation during seizures. The insula is deeply embedded within the lateral sulcus and functions as an integrative center for autonomic, sensory, and emotional information. Seizure activity in the insular cortex can disturb parasympathetic output, leading to phenomena such as hypersalivation. This abnormal discharge, affecting the nearby gustatory and autonomic pathways, is the basis for the clinical sign observed. Patients with insular seizures may present with autonomic symptoms (e.g., hypersalivation, nausea) that can be mistaken for seizures from other regions. However, when hypersalivation predominates along with possible gustatory or visceral auras, clinical suspicion should lean toward an insular focus. Differential diagnoses include mesial temporal lobe epilepsy and seizures originating from the opercular region, which can display overlapping semiology. Detailed patient history, ictal EEG (and possibly invasive EEG with depth electrodes), along with high\u2010resolution MRI, are essential to distinguish an insular focus. Functional imaging (PET/SPECT) may further assist in localization. Standard treatment involves the use of antiseizure medications. In women of child\u2010bearing age or during pregnancy/lactation, agents with a favorable teratogenic profile such as lamotrigine or levetiracetam are preferred. For medically refractory cases with clear localization to the insula, surgical evaluation\u2014including possibilities for insular resection after thorough pre\u2010surgical workup\u2014is recommended. Management should always consider both seizure control and safety during pregnancy or while lactating. Among the options provided, Option A (Insula) most accurately corresponds with the autonomic sign of hypersalivation observed in the seizure. The originally marked answer (Option B) lacks supportive evidence given the clinical scenario, making Option A the preferred selection. \u2022 Ictal hypersalivation is a red flag for autonomic involvement, often pointing toward insular seizure onset.\n\u2022 Detailed semiologic analysis can help differentiate insular seizures from other focal epilepsies, such as those of the temporal or opercular regions.\n\u2022 In women with epilepsy, always consider the safety profile of antiseizure medications during pregnancy and lactation. Recent studies and advanced neuroimaging techniques have emphasized the role of the insula in generating autonomic features during seizures. With further insights from invasive monitoring and functional imaging, the insula is increasingly recognized as a distinct epileptogenic zone where hypersalivation is a key clinical marker.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Same as above Q, asked about the treatment?",
    "option_a": "Carbamazepine (not one of the options)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "The question pertains to the treatment of a neurological condition, most consistent with trigeminal neuralgia, which is characterized by sudden, severe, lancinating facial pain. Carbamazepine is recognized as the first\u2010line treatment in this condition. Trigeminal neuralgia is usually caused by vascular compression at the root entry zone of the trigeminal nerve, leading to demyelination and subsequent hyperexcitability of the nerve fibers. This results in the classic paroxysmal pain attacks. Patients typically present with episodes of sharp, shooting pain in the distribution of one or more branches of the trigeminal nerve. Pain is often triggered by activities such as talking, chewing, or light touch to the face. Diagnosis is primarily clinical, made by the characteristic history of brief, intense facial pain. Neuroimaging (MRI) may be employed to exclude secondary causes (e.g., multiple sclerosis, tumors, or other structural causes) that might mimic primary trigeminal neuralgia. Carbamazepine is the first-line medication due to its efficacy in reducing ectopic nerve firing. Other medications (such as oxcarbazepine, gabapentin, or lamotrigine) can be considered if carbamazepine is not tolerated or contraindicated. For pregnant patients, carbamazepine is categorized as having potential risks (category D in some jurisdictions) and must be used only when benefits outweigh the risks, with careful monitoring and appropriate dose adjustments. In lactating mothers, carbamazepine is excreted in breast milk; therefore, infants should be monitored for side effects, and alternative treatments may be considered if necessary. Despite the actual list of options being incomplete\u2014with option A (Carbamazepine) not originally present\u2014the marked answer aligns with established clinical guidelines. This indicates that the intended correct answer was indeed Carbamazepine. It is vital to remember that carbamazepine requires monitoring for adverse effects such as hyponatremia, hepatic dysfunction, and hematological abnormalities. Additionally, counseling patients regarding lifestyle modifications and trigger avoidance can complement pharmacologic management. Recent clinical studies and updated guidelines from neurology associations continue to validate carbamazepine as the first-line treatment for trigeminal neuralgia, with emerging data supporting personalized treatment plans based on patient-specific factors. Management during pregnancy and lactation is complex and requires balancing the therapeutic benefit for the mother with potential risks to the fetus or neonate, with multidisciplinary input from neurology, obstetrics, and pediatrics.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient has MTLE on 2 anti-seizure medication but still has monthly seizures next?",
    "option_a": "Start workup for epilepsy Surgery",
    "option_b": "add 3rd AED",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Drug\u2010resistant epilepsy is defined as the failure to achieve sustained seizure freedom after trials of at least two appropriate and tolerated anti\u2010seizure medications. In mesial temporal lobe epilepsy (MTLE), this definition has important therapeutic implications, including the need for surgical evaluation. MTLE is often associated with hippocampal sclerosis which creates an epileptogenic focus. Recurrent seizures occur due to abnormal neuronal excitability and circuitry within the mesial temporal structures. Continuous seizures despite two well-chosen AEDs indicate that the underlying pathology is refractory to medical therapy. A patient with MTLE who continues to have monthly seizures despite being on two medications fits the profile of medically refractory epilepsy. The persistence of seizures has significant impacts on quality of life and increases the risk of injury and other complications. Evaluation for drug-resistant epilepsy typically involves detailed video EEG monitoring, high-resolution MRI focusing on temporal lobe structures, neuropsychological testing, and sometimes PET/SPECT imaging as part of a presurgical workup. Differential diagnoses include other focal epilepsies and seizure mimics, which are largely clarified by imaging and EEG findings. Current guidelines recommend that, once drug resistance is established, a patient be referred for a presurgical evaluation. First-line management initially involves adequate trials of two AEDs, and if seizures continue, the next tier is a comprehensive presurgical workup. Special considerations in pregnancy and lactation include multidisciplinary coordination to minimize both seizure risk and medication side effects; in surgical candidates, the risks and benefits of surgery during childbearing years are carefully weighed. Option A (Start workup for epilepsy surgery) is correct as the patient meets criteria for drug-resistant epilepsy, making further AED trials less likely to achieve seizure control. Option B (add a third AED) is generally not supported by evidence in drug-resistant MTLE, as adding further medications often does not lead to additional benefit and may increase side effects. 1. Failure of two adequately chosen and tolerated AEDs defines drug-resistant epilepsy. 2. MTLE is the most common form of refractory focal epilepsy and is a leading candidate for epilepsy surgery. 3. A comprehensive presurgical workup includes video EEG, MRI, and neuropsychological evaluation. Recent guidelines by the International League Against Epilepsy (ILAE) and the American Academy of Neurology (AAN) support early surgical evaluation in patients with drug-resistant MTLE. Surgical outcomes have been shown to offer superior seizure control and quality-of-life improvements compared to polytherapy adjustments in appropriately selected patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Female young Epileptic patient on Topamax has decreased concentration what to switch to?",
    "option_a": "Lamotrigine",
    "option_b": "Phenytoin",
    "option_c": "Lacosamide",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Topiramate (Topamax) is a broad-spectrum AED that is effective for seizures but is known for its adverse effects on cognition, including decreased concentration. Lamotrigine is another AED that has a more favorable cognitive side-effect profile. Topiramate exerts its anti-seizure effect partly through sodium channel blockage and enhancement of GABAergic activity; however, its inhibition of carbonic anhydrase and other neurochemical mechanisms may underlie its cognitive adverse effects. Lamotrigine modulates voltage-gated sodium channels with less impact on cognitive function. A young female patient experiencing decreased concentration while on Topamax is manifesting a common side effect of this medication. Switching to lamotrigine can preserve seizure control while minimizing cognitive complaints. The evaluation of cognitive side effects in epilepsy involves clinical history, assessment of medication adherence, and sometimes neuropsychological testing. Differential considerations include side effects from other AEDs or concurrent mood/anxiety disorders; however, the characteristic profile of Topamax often points to its cognitive effects. The first step in management is to consider switching from Topamax to another AED with a lower risk of cognitive impairment. Lamotrigine is recommended as a first-line alternative due to its efficacy and better cognitive profile. In pregnancy and lactation, lamotrigine is generally preferred (with appropriate monitoring of serum levels), whereas topiramate has been associated with teratogenic risks. Option A (Lamotrigine) is correct because it addresses the cognitive side effects while providing seizure control. Option B (Phenytoin) is less suitable, as it has its own cognitive and other side effects, and Option C (Lacosamide) does not have as clear an advantage in minimizing cognitive dysfunction compared to lamotrigine. 1. Topiramate is well-known for impairing concentration and cognitive processing. 2. Lamotrigine is a preferred alternative for patients concerned about cognitive side effects. 3. Consideration of AED side-effect profiles is crucial in women of childbearing age. Recent studies and consensus guidelines stress the importance of balancing seizure control with quality of life. Lamotrigine's favorable cognitive profile and safety data during pregnancy make it a preferred choice in such cases.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of around 30 years old female patient with bizarre nocturnal movements, localization?",
    "option_a": "Frontal operculum >>> less likely b/ semiology (profuse salivation, Mastication, salivation, swallowing, laryngeal symptoms, orofacial apraxia, and sometimes facial clonic activity)",
    "option_b": "dorsomedial (SMA)",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Focal seizures originating from the frontal lobe can present with varied motor phenomena based on the region of onset. The localization of seizure onset can often be deduced from the semiology or the pattern of clinical manifestations observed during the event. Seizures arising from the dorsomedial frontal region, especially the supplementary motor area (SMA), typically produce complex motor behaviors, including bizarre or hypermotor movements during sleep. In contrast, seizures in the frontal operculum are usually associated with marked oral or facial symptoms such as hypersalivation, mastication, and swallowing automatisms. A 30-year-old female with bizarre nocturnal movements without prominent oroalimentary automatisms (such as profuse salivation or facial clonic activity) is more suggestive of an SMA (dorsomedial frontal) origin rather than the frontal operculum. Video EEG monitoring combined with detailed seizure semiology and high-resolution imaging (MRI) are used to localize the seizure onset zone. Differential diagnoses include frontal opercular seizures (which characteristically include orofacial manifestations) and parasomnias. Careful review of the clinical description helps differentiate these entities. Once the localization is established via video EEG and imaging, treatment is tailored accordingly with AEDs or surgical evaluation in drug-resistant cases. In refractory cases, surgical resection or neuromodulation may be considered. For women, especially regarding pregnancy and lactation, the chosen AED should have a favorable teratogenic profile with appropriate counseling and monitoring. Option A (Frontal operculum) is incorrect because the semiology described (bizarre movements without prominent oral automatisms) is less typical for opercular seizures. Option B (dorsomedial, SMA) is correct as it better accounts for the bizarre nocturnal movements described. The absence of the detailed options C and D reinforces the need to select the localization most consistent with the clinical picture. 1. Bizarre hypermotor nocturnal seizures are most suggestive of an SMA (dorsomedial frontal) origin. 2. Frontal operculum seizures almost always include significant oroalimentary symptoms. 3. Detailed seizure semiology is critical for accurate localization. Recent publications on focal epilepsy have refined the distinctions between various frontal lobe seizure types. Updates in neuroimaging and video EEG monitoring continue to clarify how semiological details correlate with the epileptogenic zone, reinforcing the appropriateness of SMA localization in cases with the described semiology.",
    "exam_year": "2021",
    "exam_type": "Part I"
  }
]